The Fellow on Call: The Heme/Onc Podcast

Exploring Cold Agglutinin Disease and other acquired hemolytic anemias, the podcast covers diagnosis, management, and advancements in treatments like rituximab. It also delves into PNH, spursal anemia, and medication-induced hemolytic anemia, emphasizing the importance of personalized treatment plans and medication reconciliation.

Explore the complexities of managing warm autoimmune hemolytic anemia, from diagnostic workups to treatment strategies. Learn about challenges with blood transfusions, early connection with the blood bank, and using immune suppression for long-term remission. Dive into case studies, treatment approaches using retuximab and steroids, and monitoring parameters for non-responsive cases. Discover post-treatment care, tapering steroids, and alternative therapies for relapse and refractory cases.

Explore rare inherited conditions causing hemolytic anemia, including membranopathies and enzyme deficiencies. Learn about hereditary spherocytosis, hereditary elliptocytosis, G6PD deficiency, and PK deficiency. Discover diagnosis and treatment considerations for these disorders, and recent advances in treatment options.

The podcast discusses hemolytic anemias, including the workup for acquired hemolytic anemias and G6PD deficiency. They cover when to suspect these conditions and the importance of tailored clinical assessment and management strategies.

In the final episode of the series on prostate cancer, they discuss the treatment options for metastatic castrate-resistant prostate cancer, including targeted agents like radium-223 and lutetium-177-PSMA-617. They also explore the role of PARP inhibitors in BRCA-mutated disease and the sequencing of different treatment options.

This podcast episode discusses the treatment options for metastatic castrate sensitive prostate cancer, including the lack of guidance and biomarkers for regimen selection. It also covers the importance of germline testing, the history of prostate cancer therapy, and the choice between doublet and triplet therapy. The hosts provide a case study and explore treatment options for high-volume, castrate-sensitive metastatic prostate cancer.

Explore systemic treatment options for localized prostate cancer, including risk stratification, FDA-approved PET tracers, biochemical recurrence, castrate-sensitive vs. castrate-resistant disease, and the pivotal STAMPEDE trial. Also, delve into PSMA PET imaging, the impact of Anderson receptor antagonists, and Thanksgiving dishes as a case study backdrop.

Dr. Jacob Hall, Senior Radiation Oncology resident and Chief Resident at UNC-Chapel Hill, discusses patient selection and key terms in radiation oncology for prostate cancer. They cover the role of radiation in metastatic disease, brachytherapy, and the use of proton therapy. The podcast also includes humorous camping stories and discussions on treatment options and hypofractionation in prostate cancer radiation therapy.

Dr. Sanjay Patel, a urologic oncologist, joins the hosts to discuss prostate cancer management. They cover topics such as determining biopsy candidacy, the role of MRI in diagnosis, steps involved in a biopsy, and when additional imaging is needed. They also explore surgical approaches, when pelvic lymph node dissection is recommended, and active surveillance. The podcast provides valuable insights into the management of localized prostate cancer.

In this podcast, Vineetha Thomas, a clinical pharmacist specializing in genitourinary oncology, discusses the selection of drugs for prostate cancer, their side effects, and the role of chemotherapy. They also explore specific medications like prednisone, sipuleucel-T, radium 223, and lutetium-177. Additionally, they examine the importance of monitoring bone health in prostate cancer patients and the role of clinical pharmacists in prostate cancer treatment.